Last reviewed · How we verify
Linagliptin / Metformin Oral Tablet
Linagliptin / Metformin Oral Tablet is a DPP-4 inhibitor / Biguanide combination Small molecule drug developed by Universidad de Guanajuato. It is currently FDA-approved for Type 2 diabetes mellitus. Also known as: Combined treatment.
Linagliptin inhibits dipeptidyl peptidase-4 (DPP-4) to increase incretin levels, while metformin reduces hepatic glucose production and improves insulin sensitivity, together lowering blood glucose in type 2 diabetes.
Linagliptin inhibits dipeptidyl peptidase-4 (DPP-4) to increase incretin levels, while metformin reduces hepatic glucose production and improves insulin sensitivity, together lowering blood glucose in type 2 diabetes. Used for Type 2 diabetes mellitus.
At a glance
| Generic name | Linagliptin / Metformin Oral Tablet |
|---|---|
| Also known as | Combined treatment |
| Sponsor | Universidad de Guanajuato |
| Drug class | DPP-4 inhibitor / Biguanide combination |
| Target | DPP-4 (dipeptidyl peptidase-4) / AMPK pathway |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | FDA-approved |
Mechanism of action
Linagliptin is a DPP-4 inhibitor that prevents the degradation of glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), thereby enhancing glucose-dependent insulin secretion and reducing glucagon secretion. Metformin is a biguanide that decreases hepatic gluconeogenesis and improves peripheral insulin sensitivity. The combination provides complementary mechanisms to reduce hyperglycemia in type 2 diabetes mellitus.
Approved indications
- Type 2 diabetes mellitus
Common side effects
- Hypoglycemia
- Gastrointestinal disturbance (nausea, diarrhea)
- Headache
- Nasopharyngitis
Key clinical trials
- Efficacy and Safety of Madalena Association in the Treatment of Type II Diabetes Mellitus (PHASE3)
- Bioequivalence Study to Compare Empagliflozin/Linagliptin/Metformin HCL 25mg/5mg/1000mg Extended-Release Tablets Versus Trijardy® XR Extended Release Film Coated Tablets (PHASE1)
- A Study to Evaluate the Safety and Pharmacokinetics of Dapagliflozin, Linagliptin, and Metformin in Healthy Adults: Fed State Study (PHASE1)
- A Study to Evaluate the Safety and Pharmacokinetics of Dapagliflozin, Linagliptin, and Metformin in Healthy Adults (PHASE1)
- Safety and Efficacy of the Combination of Empagliflozin and Linagliptin Compared to Linagliptin Alone Over 24 Weeks in Patients With Type 2 Diabetes (PHASE3)
- Real-World Evaluation of Omarigliptin for Type 2 Diabetes Meliitus in Bangladesh (PHASE4)
- HSK7653 Metformin Add-on Study in Patients With Type 2 Diabetes Mellitus (PHASE3)
- Effects of Glucose Lowering Agents in South Asian Women With Impaired Glucose Tolerance or Impaired Fasting Glucose (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Linagliptin / Metformin Oral Tablet CI brief — competitive landscape report
- Linagliptin / Metformin Oral Tablet updates RSS · CI watch RSS
- Universidad de Guanajuato portfolio CI
Frequently asked questions about Linagliptin / Metformin Oral Tablet
What is Linagliptin / Metformin Oral Tablet?
How does Linagliptin / Metformin Oral Tablet work?
What is Linagliptin / Metformin Oral Tablet used for?
Who makes Linagliptin / Metformin Oral Tablet?
Is Linagliptin / Metformin Oral Tablet also known as anything else?
What drug class is Linagliptin / Metformin Oral Tablet in?
What development phase is Linagliptin / Metformin Oral Tablet in?
What are the side effects of Linagliptin / Metformin Oral Tablet?
What does Linagliptin / Metformin Oral Tablet target?
Related
- Drug class: All DPP-4 inhibitor / Biguanide combination drugs
- Target: All drugs targeting DPP-4 (dipeptidyl peptidase-4) / AMPK pathway
- Manufacturer: Universidad de Guanajuato — full pipeline
- Therapeutic area: All drugs in Diabetes
- Indication: Drugs for Type 2 diabetes mellitus
- Also known as: Combined treatment
- Compare: Linagliptin / Metformin Oral Tablet vs similar drugs
- Pricing: Linagliptin / Metformin Oral Tablet cost, discount & access